PROLOR Biotech, Inc. (PBTH)

[mlkrborn]

PROLOR Biotech announces 'positive' top-line results from pilot study of its long-acting human growth hormone injected twice per month (PBTH) 6.16 : Co announced positive top-line results from a post-Phase II clinical study of its long-acting CTP-modified version of human growth hormone (hGH-CTP) in growth hormone deficient adults. The data show that two injections of hGH-CTP per month have the potential to replace 30 consecutive daily injections of currently marketed human growth hormone. " The results from this new pilot study indicate that hGH-CTP may be able to achieve an even better administration regimen--requiring injections just twice per month. This is encouraging news for growth hormone deficient patients who would like to minimize their injection regimen."